Literature DB >> 23027555

Impairment of adenosine A3 receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo.

Matt Butler1, Devika Sanmugalingam, Victoria J Burton, Tammy Wilson, Ruth Pearson, Robert P Watson, Philip Smith, Scott J Parkinson.   

Abstract

Adenosine possesses potent anti-inflammatory properties which are partly mediated by G(i) -coupled adenosine A3 receptors (A3Rs). A3R agonists have shown clinical benefit in a number of inflammatory conditions although some studies in A3R-deficient mice suggest a pro-inflammatory role. We hypothesised that, in addition to cell signalling effects, A3R compounds might inhibit neutrophil chemotaxis by disrupting the purinergic feedback loop controlling leukocyte migration. Human neutrophil activation triggered rapid upregulation of surface A3R expression which was disrupted by pre-treatment with either agonist (Cl-IB-MECA) or antagonist (MRS1220). Both compounds reduced migration velocity and neutrophil transmigration capacity without impacting the response to chemokines per se. Similar effects were observed in murine neutrophils, while cells from A3R-deficient mice displayed a constitutively impaired migratory phenotype indicating compound-induced desensitisation and genetic ablation had the same functional outcome. In a dextran sodium sulphate-induced colitis model, A3R-deficient mice exhibited reduced colon pathology and decreased tissue myeloperoxidase levels at day 8 - consistent with reduced neutrophil recruitment. However, A3R-deficient mice were unable to resolve the dextran sodium sulphate-induced inflammation and had elevated numbers of tissue-associated bacteria by day 21. Our data indicate that A3Rs play a role in neutrophil migration and disrupting this function has the potential to adversely affect innate immune responses.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027555     DOI: 10.1002/eji.201242655

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

Review 1.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 2.  Adenosine and gastrointestinal inflammation.

Authors:  Sean P Colgan; Blair Fennimore; Stefan F Ehrentraut
Journal:  J Mol Med (Berl)       Date:  2013-01-08       Impact factor: 4.599

Review 3.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

Review 4.  The inflammatory tissue microenvironment in IBD.

Authors:  Sean P Colgan; Valerie F Curtis; Eric L Campbell
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

Review 5.  Targeting immunosuppressive adenosine in cancer.

Authors:  Dipti Vijayan; Arabella Young; Michele W L Teng; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2017-10-23       Impact factor: 60.716

6.  The Myc 3' Wnt responsive element regulates neutrophil recruitment after acute colonic injury in mice.

Authors:  Wesley M Konsavage; Jennifer N Roper; Faoud T Ishmael; Gregory S Yochum
Journal:  Dig Dis Sci       Date:  2013-05-03       Impact factor: 3.199

Review 7.  Purinergic signalling and immune cells.

Authors:  Geoffrey Burnstock; Jean-Marie Boeynaems
Journal:  Purinergic Signal       Date:  2014-10-29       Impact factor: 3.765

Review 8.  Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy.

Authors:  Taketo Kato; Johannes F Fahrmann; Samir M Hanash; Jody Vykoukal
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

9.  The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis.

Authors:  Luca Antonioli; Elena Lucarini; Catia Lambertucci; Matteo Fornai; Carolina Pellegrini; Laura Benvenuti; Lorenzo Di Cesare Mannelli; Andrea Spinaci; Gabriella Marucci; Corrado Blandizzi; Carla Ghelardini; Rosaria Volpini; Diego Dal Ben
Journal:  Cells       Date:  2020-06-21       Impact factor: 6.600

Review 10.  Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?

Authors:  Tiziana Vaisitti; Francesca Arruga; Silvia Deaglio
Journal:  Int J Mol Sci       Date:  2018-04-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.